SK Hynix vs TransMedics Group Inc — how do they compare? SK Hynix trades at $169.03 (market cap $891.31B), while TransMedics Group Inc trades at $77.87 (market cap $2.74B). The key difference: SK Hynix is far larger — about 325.3× TransMedics Group Inc's market cap, and SK Hynix pays a 0.06% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold SK Hynix for 10 Days and TransMedics Group Inc for 24 Days on average.
| SKHY | TMDX | |
|---|---|---|
Market Cap | $891.31B | $2.74B |
Volume | 22,268,296 | 949,331 |
Sector | Technology | Health |
52-Week High | $198.63 | $150.42 |
52-Week Low | $126.79 | $61.99 |
Typical Hold Time | 10 Days | 24 Days |
Enterprise Value | $841.45B | $3.13B |
Dividend Yield | 0.06% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TransMedics Group (TMDX) trades at $77.87, down 3.95% on the day, amid a bearish technical signal and recent earnings misses. The company maintains strong profitability with a 22.69% net income margin and 36.28% ROE, though 2026 projections show margin compression. Analyst consensus remains bullish with a $99.75 price target, but sentiment is clouded by multiple legal investigations into fiduciary duties announced in late August and September 2026.
The stock faces near-term pressure from technical weakness and legal overhangs, but solid fundamentals and analyst conviction suggest long-term potential if execution improves. Key risks include ongoing legal scrutiny, margin pressures from heavy investment, and volatility around future earnings reports.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
SK hynix is a South Korean semiconductor company that manufactures memory products, including DRAM and NAND flash. Its high-bandwidth memory (HBM) products are designed for high-performance computing and AI applications.
Read more on SKHY →TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →